目的 探讨金鸡胶囊联合甲硝唑呋喃唑酮栓治疗慢性盆腔炎的临床效果。方法 选取2016年3月—2017年12月在澄迈县人民医院治疗的慢性盆腔炎患者126例，随机分成对照组（63例）和治疗组（63例）。对照组患者隔日睡前取甲硝唑呋喃唑酮栓1枚置于阴道后穹窿部，治疗组患者在对照组用药基础上口服金鸡胶囊，4粒/次，3次/d。两组患者均治疗15 d。观察两组患者临床疗效，同时比较治疗前后两组患者血清超敏C反应蛋白（hs-CRP）和单核细胞趋化蛋白1（MCP-1）水平，视觉模拟评分（VAS）和症状积分及不良反应情况。结果 治疗后，对照组临床有效率为85.71%，显著低于治疗组的96.83%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清hs-CRP和MCP-1水平均显著降低（P<0.05），且治疗后治疗组血清hs-CRP和MCP-1水平明显低于对照组（P<0.05）。治疗后，两组患者VAS评分和症状积分均显著降低（P<0.05），且治疗后治疗组患者VAS评分和症状积分明显低于对照组（P<0.05）。治疗期间，治疗组患者不良反应发生率为4.76%，明显低于对照组的17.46%，两组比较差异具有统计学差异（P<0.05）。结论 金鸡胶囊联合甲硝唑呋喃唑酮栓治疗慢性盆腔炎临床疗效显著，安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Jinji Capsules combined with Metronidazole and Furazolidone Suppositories in treatment of chronic pelvic inflammatory disease. Methods Patients (126 cases) with chronic pelvic inflammatory disease in Chengmai People's Hospital from March 2016 to December 2017 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were administered with Metronidazole and Furazolidone Suppositories in posterior fornix at bedtime, 1 suppository/time. Patients in the treatment group were po administered with Jinji Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the serum hs-CRP and MCP-1 levels, VAS scores, symptom scores, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.71%, which was significantly lower than 96.83% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the hs-CRP and MCP-1 levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the VAS and symptom scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 4.76%, which was significantly lower than 17.46% in the control group, with significant difference between two groups (P<0.05). Conclusion Jinji Capsules combined with Metronidazole and Furazolidone Suppositories has significant clinical effect in treatment of chronic pelvic inflammatory disease with high safety, which has a certain clinical application value.